These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
336 related items for PubMed ID: 18338379
1. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. Chamoux E, Houde N, L'Eriger K, Roux S. J Cell Physiol; 2008 Aug; 216(2):536-42. PubMed ID: 18338379 [Abstract] [Full Text] [Related]
10. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Tat SK, Padrines M, Theoleyre S, Couillaud-Battaglia S, Heymann D, Redini F, Fortun Y. Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945 [Abstract] [Full Text] [Related]
12. Osteoprotegerin: multiple partners for multiple functions. Baud'huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF, Heymann D. Cytokine Growth Factor Rev; 2013 Oct; 24(5):401-9. PubMed ID: 23827649 [Abstract] [Full Text] [Related]
13. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI. Cancer Res; 2007 Jan 01; 67(1):202-8. PubMed ID: 17210700 [Abstract] [Full Text] [Related]
14. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system. Tanaka S. Am J Nephrol; 2007 Jan 01; 27(5):466-78. PubMed ID: 17652963 [Abstract] [Full Text] [Related]